The aetiologies of epilepsy.


Journal

Epileptic disorders : international epilepsy journal with videotape
ISSN: 1950-6945
Titre abrégé: Epileptic Disord
Pays: United States
ID NLM: 100891853

Informations de publication

Date de publication:
01 Feb 2021
Historique:
entrez: 15 3 2021
pubmed: 16 3 2021
medline: 27 10 2021
Statut: ppublish

Résumé

The identification of the aetiology of a patient's epilepsy is instrumental in the diagnosis, prognostic counselling and management of the epilepsies. Indeed, the aetiology can be important for determining the recurrence risk of single seizures and so for making a diagnosis of epilepsy. Here, we divide the aetiologies into six categories: structural, genetic, infectious, metabolic, immune (all of which are part of the International League Against Epilepsy [ILAE] classification system) and neurodegenerative (which we have considered separately because of its growing importance in epilepsy). These are not mutually exclusive categories and many aetiologies fall into more than one category. Indeed, genetic factors probably play a role, to varying degrees, in the risk of seizures in all people with epilepsy. In each of the categories, we discuss what we regard as the most important aetiologies; importance being determined not only by prevalence but also by clinical significance. The introduction contains information suitable for level 1 competency (entry level), whilst the subsequent sections contain information aimed at level 2 competency (proficiency level) as part of the new ILAE competency-based curriculum. As we move towards precision medicine and targeted therapies, so aetiologies will play an even greater role in the management of epilepsy.

Identifiants

pubmed: 33720020
pii: epd.2021.1255
doi: 10.1684/epd.2021.1255
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-16

Auteurs

Simona Balestrini (S)

UCL Queen Square Institute of Neurology, Member of the ERN EpiCARE, London, UK, Chalfont Centre for Epilepsy, Bucks, UK.

Alexis Arzimanoglou (A)

Department of Paediatric Clinical Epileptology and Functional Neurology, University Hospitals of Lyon (HCL), Member of the ERN EpiCARE, Lyon, France, Epilepsy Research Program, Epilepsy Unit, San Juan de Dios Paediatric Hospital, Member of the ERN EpiCARE, Barcelona, Spain.

Ingmar Blümcke (I)

Institute of Neuropathology, University Hospitals Erlangen, Collaborating Partner of the ERN EpiCARE, Erlangen, Germany.

Ingrid E Scheffer (IE)

University of Melbourne, Austin Health and Royal Children's Hospital, Florey and Murdoch Children's Research Institutes, Melbourne, Australia.

Samuel Wiebe (S)

Cumming School of Medicine, University of Calgary, Canada.

Johan Zelano (J)

Sahlgrenska Academy and University Hospital, Member of the ERN EpiCARE, Gothenburg, Sweden, Wallenberg Center for Molecular and Translational Medicine, Gotenburg, Sweden.

Matthew C Walker (MC)

UCL Queen Square Institute of Neurology, Member of the ERN EpiCARE, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH